Nurse Practitioner Program year 2025 Reported 2021–2025 Source: CMS Open Payments, 2026 publication

Jade Lewis

Nurse Practitioner, Family Charleston, WV Nurse Practitioner

NPI 1487192159 CMS profile 11024015

3701 MacCorkle Ave Se, Charleston, WV 25304

Open in the dashboard

General payments

$8,454

524 records reported · program years 2021–2025

Research payments

$0

Paid to them · None reported · program years 2021–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Jade Lewis of Charleston, WV is reported in the CMS Open Payments database as having received $8,454 across 524 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 97th percentile of Nurse Practitioner, Family profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

5 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $2,103 121
2024 General $1,365 81
2023 General $1,563 107
2022 General $1,420 88
2021 General $2,003 127

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Jade Lewis
  • Nurse Practitioner, Family median
  • Middle half of Nurse Practitioner, Family
  • National median

In program year 2025, general payments to Jade Lewis were reported at $2,103. Among 107,232 Nurse Practitioner, Family profiles paid that year, the median was $168 and the middle half received between $53 and $521.

Show as a table
Year Jade Lewis Nurse Practitioner, Family median Middle half National median
2019 $0 $39 $18–$91 $163
2020 $0 $32 $17–$76 $114
2021 $2,003 $124 $35–$379 $132
2022 $1,420 $141 $44–$430 $149
2023 $1,563 $154 $49–$476 $160
2024 $1,365 $165 $51–$504 $164
2025 $2,103 $168 $53–$521 $169

Breakdown

Who paid General payments · program years 2021–2025
  1. Novo Nordisk Inc $2,093 170 payments
  2. AbbVie, Inc. $1,762 85 payments
  3. Novartis Pharmaceuticals Corporation $514 29 payments
  4. AstraZeneca Pharmaceuticals LP $427 24 payments
  5. Lilly USA, LLC $382 23 payments
  6. Pfizer Inc. $377 20 payments
  7. GlaxoSmithKline, LLC. $376 30 payments
  8. Amgen Inc. $335 26 payments
  9. Bayer HealthCare Pharmaceuticals Inc. $236 14 payments
  10. Abbott Laboratories $199 11 payments
  11. Other $1,752 92 payments

Every payment, record by record

What the payments were for General payments · program years 2021–2025
  1. Food and Beverage $8,454 524 payments
Products named General payments · program years 2021–2025
  1. Ozempic $1,663 149 payments
  2. RYBELSUS $1,648 144 payments
  3. UBRELVY $1,153 52 payments
  4. QULIPTA $786 42 payments
  5. LEQVIO $379 21 payments
  6. TRELEGY ELLIPTA $301 23 payments
  7. Kerendia $236 14 payments
  8. JARDIANCE $200 11 payments
  9. VRAYLAR $195 11 payments
  10. BELSOMRA $193 10 payments
  11. Other $5,247 308 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 90 drugs

Part D claims

4,598

Median for Nurse Practitioner: 389

Drug cost

$544,404

Median for Nurse Practitioner: $21,885

Branded share of claims

17.6%

Median for Nurse Practitioner: 19.6%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Ozempic Semaglutide Brand 87 $162,425
Eliquis Apixaban Brand 58 $60,971
Jardiance Empagliflozin Brand 28 $48,567
Trelegy Ellipta Fluticasone/Umeclidin/Vilanter Brand 23 $41,582
Mounjaro Tirzepatide Brand 21 $36,460
Rybelsus Semaglutide Brand 21 $36,318
Farxiga Dapagliflozin Propanediol Brand 22 $34,329
Entresto Sacubitril/Valsartan Brand 16 $25,537
Linzess Linaclotide Brand 12 $18,268
Vascepa Icosapent Ethyl Brand 19 $17,900

The 10 drugs with the highest cost, of 90 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 229,976 Part D prescribers listed as Nurse Practitioner; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 50 billing codes

Paid by Medicare

$43,836

Of which drugs: $70

Medicare patients

104

Average age 71

Services billed

1,198

65 women, 39 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 49%
Depression 47%
Diabetes 34%
Ischemic heart disease 33%
Chronic kidney disease 26%
COPD 19%
Atrial fibrillation 18%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Injection, triamcinolone acetonide, not otherwise specified, 10 mg J3301 Office 19 95 $60

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 23 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
RYBELSUS
  • Novo Nordisk Inc $162
$162 21 —
Ozempic
  • Novo Nordisk Inc $162
$162 87 —
UBRELVY
  • AbbVie, Inc. $117
$117 — —
QULIPTA
  • AbbVie, Inc. $117
$117 — —
VRAYLAR
  • AbbVie, Inc. $86
$86 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 23 in the dashboard with a free account

Records

524 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Nurse Practitioner, Family in West Virginia

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record